GleamWall
中文EN

RGEN REPLIGEN CORP

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 730272 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY13.8%
TTM net income YoY-779.2%
TTM EPS YoY-1,150.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin53.8%
Operating margin2.3%
Net margin-1.5%
FCF margin13.2%
EBITDA margin11.9%

Returns

ROE-0.6%
ROA-0.4%
ROIC (approx.)0.5%
Asset turnover0.28x

Leverage & solvency

Liabilities / assets28.5%
Debt / equity0.27x
Current ratio9.88x
Interest coverage0.81x

Cash quality & payout

Operating cash flow / net income-11.00x
Accruals ratio-4.8%
Payout ratio—
Capex / revenue2.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$738.26M$634.44M
Cost of revenue$352.01M$359.79M
Gross profit$386.25M$274.64M
R&D expense$54.18M$43.20M
SG&A expense$290.51M$263.37M
Operating income$55.17M-$35.11M
Interest expense$21.51M$20.73M
Pretax income$62.38M-$27.04M
Income tax$13.49M-$1.52M
Net income$48.89M-$25.51M
EBITDA$133.91M$34.56M
EPS (basic)0.87-0.46
EPS (diluted)0.86-0.46
Weighted avg. shares (diluted)56,56155,937
Balance sheet
Cash & equivalents$566.02M$757.36M
Short-term investments$201.61M$0
Receivables$158.59M$134.12M
Inventory$170.46M$142.96M
Current assets$1.14B$1.07B
PP&E, net$186.61M$197.74M
Goodwill$1.11B$1.03B
Intangibles$386.15M$397.90M
Total assets$2.95B$2.83B
Current liabilities$135.83M$126.79M
Long-term debt$542.21M$525.57M
Total debt$542.21M$525.57M
Total liabilities$843.57M$856.95M
Shareholders' equity$2.11B$1.97B
Net debt-$23.81M-$231.79M
Shares outstanding56.33M56.09M
Cash flow statement
Operating cash flow$117.42M$175.39M
Capital expenditure$23.52M$25.68M
Free cash flow$93.90M$149.72M
Investing cash flow-$298.47M-$86.38M
Financing cash flow-$15.21M-$82.90M
Depreciation & amortization$78.75M$69.67M
Stock-based compensation$32.60M$48.07M
Share buybacks$0$0

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.